Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren Pan

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Cancer Management and Research|July 27, 2023
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyDarren Pan, Joshua Richter
Frontiers in Oncology|February 7, 2022
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and PipedreamsDarren Pan, Joshua Richter
Current Hematologic Malignancy Reports|August 15, 2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple MyelomaDarren Pan, Joshua Richter
Blood Advances|March 10, 2020
Clinical developments in epigenetic-directed therapies in acute myeloid leukemiaDarren Pan, Raajit Rampal, John Mascarenhas
Ejhaem|November 29, 2023
Real-world multiple myeloma front-line treatment and outcomes by transplant in the United StatesJoshua Richter, Darren Pan, Taylor Salinardi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
ResponseAlfonso Molina, Drew J Winston, Darren Pan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2018
Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant RecipientsAlfonso Molina, Drew J Winston, Darren Pan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 24, 2021
Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital ExperienceDarren Pan, Alexander Coltoff, Umut Ozbek, et al.
Seminars in Oncology|April 2, 2023
Outcomes with panobinostat in heavily pretreated multiple myeloma patientsDarren Pan, Tarek H Mouhieddine, Ranjan Upadhyay, et al.
Immunotherapy|October 17, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Arvind Suresh, Darren Pan, Jodi Lipof, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cancer Management and Research|July 27, 2023
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyDarren Pan, Joshua Richter
Frontiers in Oncology|February 7, 2022
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and PipedreamsDarren Pan, Joshua Richter
Current Hematologic Malignancy Reports|August 15, 2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple MyelomaDarren Pan, Joshua Richter
Blood Advances|March 10, 2020
Clinical developments in epigenetic-directed therapies in acute myeloid leukemiaDarren Pan, Raajit Rampal, John Mascarenhas
Ejhaem|November 29, 2023
Real-world multiple myeloma front-line treatment and outcomes by transplant in the United StatesJoshua Richter, Darren Pan, Taylor Salinardi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
ResponseAlfonso Molina, Drew J Winston, Darren Pan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2018
Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant RecipientsAlfonso Molina, Drew J Winston, Darren Pan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 24, 2021
Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital ExperienceDarren Pan, Alexander Coltoff, Umut Ozbek, et al.
Seminars in Oncology|April 2, 2023
Outcomes with panobinostat in heavily pretreated multiple myeloma patientsDarren Pan, Tarek H Mouhieddine, Ranjan Upadhyay, et al.
Immunotherapy|October 17, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Arvind Suresh, Darren Pan, Jodi Lipof, et al.
Pageof 3